NKTR-102 (PEG-Irinotecan) Demonstrates Significant Anti Tumor Activity And Improved Pharmacokinetic Profile In Preclinical Studies Presented At ECCO

Nektar Therapeutics (Nasdaq: NKTR) announced positive new preclinical data regarding its proprietary product candidate, NKTR-102 (PEG-irinotecan), which is under development for the treatment of solid tumors. NKTR-102 is a PEGylated form of irinotecan created using Nektar’s innovative small molecule PEGylation technology platform. The data were presented at the 14th Annual European Cancer Conference (ECCO 14). [click link for full article]

More: continued here

Filed under: Cancer on September 28th, 2007